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INTRODUCTION
Endometrial cancer is the third most common gynecologic 
cancer, and its incidence and mortality are increasing in Korea, 
where more than 1,700 new cases are diagnosed and approxi­
mately 250 deaths occur every year from the disease [1,2]. The 
incidence rate increases every year by 6.9% and the mortality 
rate, by 6.7%. As such, the burden of this disease can be ex­
pected to increase in the near future.
The optimal management of endometrial cancer remains 
one of the most debated issues, with many differences and 
discrepancies among gynecologic oncologists. There is signifi­
cant variability in the treatment algorithms used at different 
institutions and even among physicians within the same 
institution. Unresolved questions remain as to the value and 
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extent of lymphadenectomy, the optimal adjuvant therapy for 
intermediate or high­risk endometrial cancer. 
In 2009, the Korean Gynecologic Oncology Group (KGOG) 
conducted a survey to assess surgical practice patterns for 
endometrial cancer in Korea [3]. A previous survey by KGOG 
showed substantial differences in the surgical procedures 
used for the treatment of endometrial cancer between Korean 
gynecologic oncologists. Since then, there has been level I 
evidence from randomized controlled trials for surgical and 
adjuvant treatment in the field of endometrial cancer [4­7]. 
However, certain discrepancies still exist between the clinical 
guidelines and the actual practice adopted by clinicians. To 
identify current practice patterns in the surgical and adjuvant 
management of endometrial cancer in Korea, we conducted a 
survey of KGOG members.
MATERIALS AND METHODS 
This survey was initiated by the Uterine Corpus Committee 
of the KGOG. In December 2014, we mailed the question­
naire to all 218 KGOG members. The last date for receipt 
of responses was set for February 13, 2015. The survey was 
estimated to take 10 minutes to complete and was submitted 
electronically. All data were stored automatically by the 
website SurveyMonkey (http://ko.surveymonkey.com), and 
all responses were anonymous. The respondents were asked 
about demographic characteristics, including their current 
practice settings and years since completing fellowship 
training. The respondents were asked 20 questions regarding 
surgical and adjuvant procedures for endometrial cancer. Each 
question referenced a detailed clinical scenario. The survey 
questions are provided in Supplementary Table 1. 
The data were analyzed using frequency distributions and 
nonparametric tests. In the event of missing data, percentages 
were determined on the basis of the number of responses 
received. 
RESULTS
1. Respondents’ demographics
Table 1 shows the demographics of the survey respondents. 
Of the 218 KGOG members who received the survey ques­
tionnaire, 108 (49.5%) responded. Most were men (87%) and 
were aged 41 to 50 years (52.8%). Of the respondents, 92.6% 
had completed a fellowship and 7.4% were currently fellows. 
Almost half of the respondents (47%) completed their fellow­
ship training more than 10 years ago.
2. Surgical management
Scenario 1 (mode of surgery for presumed stage I endome­
trial cancer): the patient was diagnosed with presumed stage 
I/grade 1 endometrioid adenocarcinoma. Fig. 1 shows the 
Laparotomy
Laparoscopy
Robot
What is your preference for the mode of
surgery in this scenario?
81.1%
8.5%10.4%
Fig. 1. Mode of surgery for presumed stage I disease.
Table 1. Respondents’ demographics
Variable No. (%)
Age (yr)
    30–40 21 (19.4)
    41–50 57 (52.8)
    51–60 21 (19.4)
    61–70 9 (8.3)
    >70 0
Sex
    Male 94 (87.0)
    Female 14 (13.0)
No. of years since fellowship training
    Currently in fellowship training 8 (7.4)
    Up to 5 years since completion 22 (20.4)
    6–10 years since completion 27 (25.0)
    11–15 years since completion 20 (18.5)
    >15 years since completion 31 (28.7)
No. of endometrial cancer cases managed 
  in your center (per year)
    ≤20 25 (23.1)
    21–40 30 (27.8)
    41–80 25 (23.1)
    81–100 11 (10.2)
    101–150 8 (7.4)
    >150 9 (8.3)
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respondents’ treatment preferences for the mode of surgery. 
The majority of respondents (81%) would recommend lapa­
ro scopy and only 8.5% stated laparotomy. Approximately 
10% of respondents preferred robotic surgery for this clinical 
scenario. 
Scenario 2 (management for incidentally found stage I endo­
metrial cancer): the patient was incidentally diagnosed with 
endometrial cancer. A general gynecologist performed a total 
hysterectomy and bilateral salpingo­oophorectomy without 
lymphadenectomy.
Scenario 2A (incidentally found stage I/grade 1 endometrial 
cancer): the final pathology report shows stage IA/grade 1 
endometrioid adenocarcinoma. Table 2 lists the respondents’ 
preferences in this scenario. Only 9.5% would recommend 
additional therapy. All respondents who recommended addi­
tional therapy preferred laparoscopic lymph node dissection.
Scenario 2B (incidentally found stage I/grade 3 endometrial 
cancer): the final pathology report reveals stage IA/grade 
3 disease. Table 2 lists the respondents’ preferences. The 
majority of respondents (85.6%) would recommend additional 
therapy in this scenario. Among those who recommended 
additional therapy, vaginal brachytherapy (36.4%) and 
laparoscopic lymph node dissection (34.1%) were the most 
commonly preferred options. 
Scenario 3 (extent of lymphadenectomy for presumed stage I 
disease)
Scenario 3A (presumed stage IA/grade 1 endometrial cancer): 
the patient was diagnosed with presumed stage IA/grade 1 
endometrioid adenocarcinoma based on preoperative mag­
netic resonance imaging (MRI) and biopsy. Preoperative cancer 
antigen 125 was within the normal range. Table 3 shows the 
respondents’ treatment preferences for the extent of surgery. 
Of all the respondents, 19.8% stated that lymphadenectomy 
could be omitted and 21.7% recommended selective 
lymphadenectomy based on sentinel biopsy or frozen results 
for patients with presumed stage IA disease. More than half 
of the respondents (58.5%) preferred lymphadenectomy, of 
which 31.1% preferred pelvic lymphadenectomy only, 15.1% 
preferred pelvic and para­aortic lymphadenectomy up to 
the level of the inferior mesenteric artery (IMA), and 12.3% 
preferred pelvic and para­aortic lymphadenectomy up to the 
level of the renal vein. 
Scenario 3B (presumed stage IB/grade 1 endometrial cancer): 
the patient was diagnosed with presumed stage IB/grade 1 
disease based on preoperative MRI and biopsy. Respondents’ 
preferences for the extent of surgery are shown in Table 3. The 
majority of respondents (93.3%) would recommend lymph­
adenectomy in this scenario, of which 21.4% preferred pelvic 
lymphadenectomy, 35.0% preferred pelvic and para­aortic 
lymphadenectomy up to the IMA level, and 36.9% preferred 
Table 2. Surveyed Korean Gynecologic Oncology Group members’ 
additional therapy recommendations for incidentally found stage I 
endometrial cancer
Scenario 2A* 2B†
Final pathology IAG1 IAG3
Recommend adjuvant therapy (%) 9.5 85.6
Type of therapy recommended (%)
    Laparoscopy for lymph node dissection 100 34.1
    Laparotomy for lymph node dissection 0 3.4
    Vaginal brachytherapy 0 36.4
    Whole pelvic radiation therapy 0 18.2
    Chemotherapy 0 8
*2A, incidentally found stage I/grade 1 endometrial cancer. †2B, inci­
dentally found stage I/grade 3 endometrial cancer.
Table 3. Extent of lymphadenectomy for presumed stage I disease
Scenario 3A* 3B† 3C‡
Preopative biopsy results (grade) 1 1 3
Preopative MRI results (myometrial invasion) Less than half More than half More than half
Extent of surgery (%)
    SH/BSO 19.8 0 0
    SH/BSO+sentinel biopsy   6.6   2.9 1.9
    SH/BSO+selective lymphadenectomy with frozen results 15.1   3.9 1.0
    SH/BSO+PLND 31.1 21.4 10.7
    SH/BSO+PLND/PALND (up to IMA level) 15.1 35.0 34.0
    SH/BSO+PLND/PALND (up to renal vein level) 12.3 36.9 52.4
BSO, bilateral salpingo­oophorectomy; IMA, inferior mesenteric artery; MRI, magnetic resonance imaging; PALND; para­aortic lymph node 
dissection; PLND, pelvic lymph node dissection; SH, simple hysterectomy.
*3A, presumed stage IA/grade 1 endometrial cancer. †3B, presumed stage IB/grade 1 endometrial cancer. ‡3C, presumed stage IB/grade 3 
endometrial cancer.
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pelvic and para­aortic lymphadenectomy up to the level of 
the renal vein.
Scenario 3C (presumed stage IB/grade 3 endometrial cancer): 
the patient was diagnosed with presumed stage IB/grade 3 
disease based on preoperative MRI and biopsy. Respondents’ 
preferences for the extent of surgery are shown in Table 3. 
The majority of respondents (97.1%) indicated that lymphad­
enectomy would be recommended, of which 10.7% preferred 
pelvic lymphadenectomy, 34.0% preferred pelvic and para­
aortic lymphadenectomy up to the IMA level, and 52.4% 
preferred pelvic and para­aortic lymphadenectomy up to the 
level of the renal vein. 
3. Adjuvant treatment
Table 4 shows respondents’ preferences for adjuvant therapy 
in completely staged endometrial cancer. Respondents were 
asked to complete a table showing the preferred adjuvant 
therapy based on pathologic findings. In patients with stage 
IA/grade 1 disease, all respondents indicated that observation 
was preferable. Our survey reveals that more than 70% of 
members administered adjuvant therapy except stage IA/
grade 1 or stage IA/grade 2: more than 90% administered 
adjuvant therapy when patients exhibited stage IA/grade 3, 
stage IB/grade 2 or stage IB/grade 3 disease. In patients with 
stage IB/grade 3 disease, the majority of respondents (99%) 
would recommend adjuvant therapy, among which whole 
pelvic radiation therapy (WPRT) was preferred by 34.4% and 
WPRT and brachytherapy was preferred by 26%. 
Scenario 4 (adjuvant treatment for stage II): the patient has 
stage II endometrioid adenocarcinoma with less than half 
myometrial invasion. Respondents’ preferences for adjuvant 
therapy are listed in Table 5. The majority of respondents 
(89.6%) would recommend adjuvant therapy for stage II dis­
ease, among which WPRT was preferred by 31.8% and vaginal 
brachytherapy was preferred by 29.4%. 
Scenario 5 (adjuvant treatment for stage IA and positive 
cytology): the patient has stage IA/grade 1 endometrioid 
adenocarcinoma and malignant cytology. Table 5 shows the 
respondents’ preferences for adjuvant therapy. Over half of 
respondents (55%) would recommend adjuvant therapy, with 
57.7% indicating chemotherapy as their first preference. 
Scenario 6 (adjuvant treatment for stage IIIC1): The patient 
has stage IIIC1 endometrioid adenocarcinoma with more than 
half of myometrial invasion. Table 5 shows the respondents’ 
preferences for adjuvant therapy. All respondents indicated 
that adjuvant therapy should be performed in this scenario. 
Table 4. Surveyed Korean Gynecologic Oncology Group members’ adjuvant therapy recommendations for stage I endometrial cancer 
according to stage and grade
Adjuvant options (%) IAG1 IAG2 IAG3 IBG1 IBG2 IBG3
Observation 100 70.8 9.4 28.1 8.3 1
VB 0 19.8 46.9 35.4 37.6 17.7
WPRT 0 6.3 28.1 25 26 34.4
WPRT+brachytherapy 0 1 4.2 4.2 13.5 26
Chemotherapy 0 1 7.3 4.2 7.3 8.3
CCRT 0 1 4.2 3.1 7.3 12.5
CCRT, concurrent chemoradiation therapy; VB, vaginal brachytherapy; WPRT, whole pelvic radiation therapy. 
Table 5. Surveyed Korean Gynecologic Oncology Group members’ adjuvant therapy recommendations for completely staged endometrial 
cancer
Scenario Stage II Stage IA and positive cytology Stage IIIC1 Stage IIIA
Adjuvant therapy (%)
    Yes 89.6 55.3 100 95.7
    No 10.4 44.7 0 4.3
If yes, preferred treatment (%)
    1 WPRT (31.8) Chemotherapy (57.7) CCRT (53.2) Chemotherapy (42.0)
    2 VB (29.4) CCRT (17.3) Chemotherapy (28.7) CCRT (31.8)
    3 WPRT+VB (21.2) WPRT (13.5) WPRT+VB (12.8) WPRT (17.0)
    4 CCRT (14.1) Hormone therapy (7.7) WPRT (5.3) WPRT+VB (9.1)
CCRT, concurrent chemoradiotherapy; VB, vaginal brachytherapy; WPRT, whole pelvic radiation therapy. 
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More than half of the respondents who recommended 
adjuvant therapy stated that concurrent chemoradiotherapy 
(CCRT) would be their first choice of adjuvant therapy.
Scenario 7 (adjuvant treatment for stage IIIA): The patient 
has stage IIIA/grade 1 endometrioid adenocarcinoma with 
less than half myometrial invasion. Respondents’ preferences 
of adjuvant therapy are listed in Table 5. The majority of 
respondents (95.7%) suggested the use of adjuvant therapy in 
microscopic ovarian metastasis. The most common treatment 
choices were chemotherapy (42.0%) and CCRT (31.8%). 
DISCUSSION
When it came to the mode of surgery, there was a general 
consensus among KGOG members that minimally invasive 
surgery was preferable. However, we observed differences 
between KGOG members in current practice patterns for 
the treatment of endometrial cancer. This discrepancy was 
particularly prominent for the extent of surgery and adjuvant 
therapy options. 
The role of minimally invasive surgery in endometrial cancer 
is expanding. Between 2009 and 2015, there have been 
significant increases in the proportion of KGOG survey respon­
dents who think that minimally invasive surgery is appropriate 
for early­stage endometrial cancer (from 49% to 91.5% 
[n=41/84 to 97/106], p<0.001) [3]. With similar outcomes for 
laparoscopy and laparotomy in the Gynecologic Oncology 
Group (GOG) LAP2 study [7], minimally invasive surgery is 
now considered standard for the treatment of endometrial 
cancer in Korea. Similarly, a recent survey by the Society of 
Gynecologic Oncology (SGO) showed that the majority of re­
spondents (85.5%) preferred minimally invasive surgery for the 
staging of endometrial cancer [8]. However, robotic surgery is 
not commonly performed in Korea: while laparoscopy is the 
preferred option in Korea, the SGO survey showed that 97% 
of respondents now perform robotic gynecologic procedures, 
compared with 29.0% in the 2007 survey. The SGO survey 
demonstrated that more than half of the respondents who 
performed robotic surgery stated that they used it for 50% or 
more of all their gynecologic cases. 
For the extent of surgery for presumed low­risk endometrial 
cancer, there was a significant difference in opinion among 
the KGOG respondents, and we found a clear discrepancy 
between the clinical guidelines and the actual practice 
adopted by clinicians. As two large randomized controlled 
trials have demonstrated that comprehensive surgical stag­
ing does not improve progression­free or overall survival 
[5,6], the current National Comprehensive Cancer Network 
(NCCN) guidelines recommend a more selective and tailored 
lymphadenectomy approach in early­stage endometrial 
cancer [9,10]. In this survey, we observed that approximately 
60% of respondents recommended lymphadenectomy at 
least at the pelvic level. The KGOG survey performed in 2009 
showed that approximately 67% of respondents preferred 
routine pelvic lymphadenectomy [3]. As such, there has not 
been a significant decrease in the proportion of respondents 
preferring routine pelvic lymphadenectomy for early­stage 
endometrial cancer in recent years (67% to 58.5% [n=56/84 
to 62/106], p=0.249). Considering the results of surveys on 
lymphadenectomy conducted in other countries, we found 
significant variation between different geographic regions: 
While countries in Asia (72.8%) and Central Europe (55.6%) 
routinely perform lymphadenectomy, countries in the north 
and south of Europe as well as the United Kingdom, United 
States, and Canada perform routine lymphadenectomy in less 
than a third of endometrial cancer cases [11]. 
The anatomic borders of the lymphadenectomy continue to 
be controversial in intermediate­ and high­risk endometrial 
cancer. About 37% members defined the upper border of 
para­aortic lymphadenectomy as the renal vein for interme­
diate­risk endometrial cancer (presumed stage IB/grade 1), 
while more than half defined the upper border of para­aortic 
lymphadenectomy as the renal vein for high­risk endometrial 
cancer (presumed stage IB/grade 3). Compared to just 11% of 
members preferring to remove nodes to the level of the renal 
vein in the 2010 SGO survey [12], the percentage of Korean 
gynecologic oncologists performing para­aortic lymphad­
enectomy up to the renal vein is relatively high. 
Our survey is the first to assess practice patterns for adjuvant 
treatment in patients with endometrial cancer in Korea, as 
we did not ask about adjuvant practice in the 2009 survey. 
Indications for adjuvant therapy for patients with endometrial 
cancer are determined by various pathologic prognostic fac­
tors such as histologic subtype, grade, lymph node metastasis, 
myometrial invasion, and lymphovascular space invasion. 
Patient selection criteria for adjuvant therapy and optimal 
regimens for endometrial cancer have not yet been estab­
lished in clinical practice. The current NCCN guidelines allow 
a broad range of adjuvant therapy options for endometrial 
cancer. 
We observed different adjuvant therapy patterns for the 
treatment of disease confined to the uterus and for disease 
with adnexal or nodal involvement. Our survey showed that 
WPRT and/or vaginal brachytherapy are commonly performed 
for Stage I endometrial cancer. Four trials evaluated the role 
of WPRT in endometrial cancer and failed to show improved 
overall survival [13­16]. As Postoperative Radiation Therapy 
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for Endometrial Carcinoma­2 (PORTEC­2) showed that vaginal 
brachytherapy has similar vaginal and pelvic control rates 
and overall survival to those for WPRT, vaginal brachytherapy 
is a reasonable choice for patients with stage I endometrial 
cancer [4]. As evidence that this finding has been adopted 
Korea, vaginal brachytherapy was the preferred option among 
KGOG members. Despite adjuvant therapy with WPRT or 
vaginal brachytherapy, a significant proportion of patients 
still experience distant metastases. Although the role of 
adjuvant chemotherapy is currently being studied (GOG 249, 
PORTEC­3), adjuvant chemotherapy has been adopted among 
some clinicians even for the treatment of disease confined to 
the uterus. 
Among KGOG members, there is a consensus that patients 
with stage IIIA and stage IIIC1 disease need adjuvant therapy. 
However, there is a broad range of opinion on the optimal 
means of adjuvant therapy. Generally, chemotherapy or CCRT 
are the preferred options for patients with extrauterine dis­
ease. This trend may be a reflection of the current guidelines 
favoring chemotherapy based on the results of the GOG­122 
trial [17]. When we examined survey results from other coun­
tries, we found that chemotherapy was the preferred option 
for adjuvant therapy among Japanese Gynecologic Oncology 
Group members (79.9%) [18], who performed radiotherapy in 
just 13% of cases and did not consider CCRT as a treatment 
option. 
While our survey only captures the reported practice pat­
terns of 50% of KGOG members, there is clear variation among 
practicing gynecologic oncologists. This study is limited by 
both reporting biases and the response rate. In addition, we 
did not include non­endometrioid histology and considered 
only endometrioid adenocarcinoma. 
The surgical extent of lymphadenectomy is still one of the 
most controversial topics in the management of endometrial 
cancer. Furthermore, there is a broad range of options for 
adjuvant therapy in the treatment of this disease. In general, 
radiotherapy is preferred for stage I and stage II disease and 
chemotherapy is preferred for stage III disease. Currently, the 
Korean guidelines for treating endometrial cancer are in the 
process of being revised. For standardizing practice patterns 
and improving guideline adherence, further studies will be 
required to identify the differences between actual practice 
and the revised guidelines once they are published.
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